{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:09:57Z","timestamp":1790644197109,"version":"4.1.0"},"reference-count":67,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.19407","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T15:39:22Z","timestamp":1656517162000},"page":"e2219407","source":"Crossref","is-referenced-by-count":43,"title":["Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus"],"prefix":"10.1001","volume":"5","author":[{"given":"Darren Jun Hao","family":"Tan","sequence":"first","affiliation":[{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Han","family":"Ng","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe Wen Lin","family":"Tay","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Syn","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Muthiah","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore"},{"name":"National University Centre for Organ Transplantation, National University Health System, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Hui","family":"Lim","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansel Shao Pin","family":"Tang","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai En","family":"Lim","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace En Hui","family":"Lim","sequence":"additional","affiliation":[{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University, Sinagpore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Kyung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan"},{"name":"Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea"},{"name":"Yonsei Liver Center, Severance Hospital, Yonsei University Health System, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret Li Peng","family":"Teng","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore"},{"name":"National University Centre for Organ Transplantation, National University Health System, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Fung","sequence":"additional","affiliation":[{"name":"Division of Liver Transplantation, Department of Surgery, Queen Mary Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[{"name":"NAFLD (Nonalcoholic Fatty Liver Disease) Research Center, Division of Medicine, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Q.","family":"Huang","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore"},{"name":"National University Centre for Organ Transplantation, National University Health System, Singapore"},{"name":"NAFLD (Nonalcoholic Fatty Liver Disease) Research Center, Division of Medicine, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"issue":"10258","key":"zoi220558r1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"zoi220558r3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/cld.v15.2","article-title":"Development of hepatocellular carcinoma in patients with suppressed viral replication: changes in risk over time.","volume":"15","author":"Udompap","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"zoi220558r4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/liv.v40.s1","article-title":"Hepatitis B: who to treat? a critical review of international guidelines.","volume":"40","author":"Huang","year":"2020","journal-title":"Liver Int"},{"issue":"1","key":"zoi220558r5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"zoi220558r6","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J Hepatol"},{"issue":"3","key":"zoi220558r7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3350\/cmh.2016.0045","article-title":"The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy.","volume":"22","author":"Varbobitis","year":"2016","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"zoi220558r8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/apt.13895","article-title":"Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study.","volume":"45","author":"Seto","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"zoi220558r9","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.v67.4","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"zoi220558r10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"2","key":"zoi220558r11","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"zoi220558r12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jhep.2021.09.017","article-title":"Methodological challenges in meta-analysis to assess the risk of hepatocellular carcinoma between chronic hepatitis B treatments.","volume":"76","author":"Choi","year":"2021","journal-title":"J Hepatol"},{"issue":"1","key":"zoi220558r13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1186\/s12885-019-5735-9","article-title":"The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis.","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"issue":"2","key":"zoi220558r14","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cgh.2020.05.008","article-title":"Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis.","volume":"19","author":"Choi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"zoi220558r15","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000236","article-title":"Entecavir vs tenofovir in hepatocellular carcinoma prevention in chronic hepatitis B infection: a systematic review and meta-analysis.","volume":"11","author":"Cheung","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"zoi220558r16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/hep.v73.1","article-title":"Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and meta-analysis.","volume":"73","author":"Dave","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"zoi220558r17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12072-019-10005-0","article-title":"Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis.","volume":"14","author":"Li","year":"2020","journal-title":"Hepatol Int"},{"issue":"9","key":"zoi220558r18","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/jgh.v35.9","article-title":"Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis.","volume":"35","author":"Gu","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"zoi220558r19","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1159\/000507253","article-title":"Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B: a systematic review and meta-analysis.","volume":"9","author":"Liu","year":"2020","journal-title":"Liver Cancer"},{"issue":"2","key":"zoi220558r20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.5009\/gnl18546","article-title":"Nucleos(t)ide analogues for reducing hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis.","volume":"14","author":"Wang","year":"2020","journal-title":"Gut Liver"},{"issue":"12","key":"zoi220558r21","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","article-title":"Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.","volume":"5","author":"Tseng","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"zoi220558r22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/0163278702025001006","article-title":"To IPD or not to IPD? advantages and disadvantages of systematic reviews using individual patient data.","volume":"25","author":"Stewart","year":"2002","journal-title":"Eval Health Prof"},{"issue":"12","key":"zoi220558r23","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/s41416-018-0302-8","article-title":"Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint.","volume":"119","author":"Rulli","year":"2018","journal-title":"Br J Cancer"},{"issue":"71","key":"zoi220558r24","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"16","key":"zoi220558r25","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement.","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"zoi220558r26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/SLA.0000000000003672","article-title":"Survival advantage of laparoscopic versus open resection for colorectal liver metastases: a meta-analysis of individual patient data from randomized trials and propensity-score matched studies.","volume":"272","author":"Syn","year":"2020","journal-title":"Ann Surg"},{"issue":"10287","key":"zoi220558r27","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/S0140-6736(21)00591-2","article-title":"Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174?772 participants.","volume":"397","author":"Syn","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"zoi220558r28","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/jama.286.7.821","article-title":"Comparison of evidence of treatment effects in randomized and nonrandomized studies.","volume":"286","author":"Ioannidis","year":"2001","journal-title":"JAMA"},{"issue":"8","key":"zoi220558r29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw323","article-title":"Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies.","volume":"109","author":"Yao","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zoi220558r30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jamcollsurg.2019.10.003","article-title":"Use of propensity score methodology in contemporary high-impact surgical literature.","volume":"230","author":"Grose","year":"2020","journal-title":"J Am Coll Surg"},{"issue":"1","key":"zoi220558r31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"10150","key":"zoi220558r32","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"issue":"10235","key":"zoi220558r33","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S0140-6736(20)30531-6","article-title":"Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta-analysis of randomised clinical trials.","volume":"395","author":"Gaudry","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"zoi220558r34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/jrsm.v11.2","article-title":"Individual participant data meta-analysis of intervention studies with time-to-event outcomes: a review of the methodology and an applied example.","volume":"11","author":"de Jong","year":"2020","journal-title":"Res Synth Methods"},{"issue":"18","key":"zoi220558r35","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1002\/sim.5732","article-title":"A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis.","volume":"32","author":"Debray","year":"2013","journal-title":"Stat Med"},{"issue":"9","key":"zoi220558r36","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes.","volume":"24","author":"Smith","year":"2005","journal-title":"Stat Med"},{"issue":"1","key":"zoi220558r37","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/1745-6215-15-314","article-title":"An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.","volume":"15","author":"Royston","year":"2014","journal-title":"Trials"},{"key":"zoi220558r38","doi-asserted-by":"publisher","first-page":"j2250","DOI":"10.1136\/bmj.j2250","article-title":"Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards.","volume":"357","author":"Dehbi","year":"2017","journal-title":"BMJ"},{"issue":"19","key":"zoi220558r39","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.4274","article-title":"The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.","volume":"30","author":"Royston","year":"2011","journal-title":"Stat Med"},{"issue":"3","key":"zoi220558r40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"4","key":"zoi220558r41","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial.","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"issue":"3","key":"zoi220558r42","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jrsm.v10.3","article-title":"Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions.","volume":"10","author":"Schwarzer","year":"2019","journal-title":"Res Synth Methods"},{"issue":"7109","key":"zoi220558r44","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"zoi220558r45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study.","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi220558r46","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jhep.2019.03.028","article-title":"A multicenter study of entecavir vs tenofovir on prognosis of treatment-na\u00efve chronic hepatitis B in South Korea.","volume":"71","author":"Kim","year":"2019","journal-title":"J Hepatol"},{"issue":"7","key":"zoi220558r47","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1136\/gutjnl-2019-318947","article-title":"Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-na\u00efve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.","volume":"69","author":"Lee","year":"2020","journal-title":"Gut"},{"issue":"10","key":"zoi220558r48","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1111\/jgh.v35.10","article-title":"Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: a propensity score matching analysis.","volume":"35","author":"Ha","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"zoi220558r49","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/jvh.2018.25.issue-12","article-title":"Mortality, liver transplantation and hepatic complications in patients with treatment-na\u00efve chronic hepatitis B treated with entecavir vs tenofovir.","volume":"25","author":"Kim","year":"2018","journal-title":"J Viral Hepat"},{"issue":"12","key":"zoi220558r50","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1016\/j.cgh.2020.02.046","article-title":"No difference in incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection treated with entecavir vs tenofovir.","volume":"18","author":"Oh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"zoi220558r51","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s10620-020-06375-3","article-title":"Comparable incidence of hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir or tenofovir.","volume":"66","author":"Shin","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"1","key":"zoi220558r52","doi-asserted-by":"publisher","first-page":"13537","DOI":"10.1038\/s41598-020-70433-z","article-title":"Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate.","volume":"10","author":"Ha","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"zoi220558r53","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41598-020-80523-7","article-title":"Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B.","volume":"11","author":"Chang","year":"2021","journal-title":"Sci Rep"},{"issue":"11-12","key":"zoi220558r54","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/apt.16116","article-title":"Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-na\u00efve patients with chronic hepatitis B\u2013related compensated cirrhosis in Taiwan.","volume":"52","author":"Hu","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"zoi220558r55","first-page":"3882","article-title":"Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan: a retrospective study.","volume":"10","author":"Chen","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"1","key":"zoi220558r56","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","article-title":"Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China.","volume":"158","author":"Yip","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"zoi220558r57","first-page":"370","article-title":"No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.","volume":"70","author":"Su","year":"2021","journal-title":"Gut"},{"issue":"2","key":"zoi220558r58","doi-asserted-by":"publisher","first-page":"271","DOI":"10.14309\/ajg.0000000000000428","article-title":"Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B.","volume":"115","author":"Hsu","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"zoi220558r59","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s12072-021-10234-2","article-title":"Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.","volume":"15","author":"Lee","year":"2021","journal-title":"Hepatol Int"},{"issue":"4","key":"zoi220558r60","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1053\/j.gastro.2010.06.042","article-title":"Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.","volume":"139","author":"Woo","year":"2010","journal-title":"Gastroenterology"},{"issue":"6","key":"zoi220558r61","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/apt.2014.39.issue-6","article-title":"Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA.","volume":"39","author":"Gao","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"zoi220558r62","doi-asserted-by":"publisher","first-page":"335","DOI":"10.14218\/JCTH.2020.00164","article-title":"Tenofovir alafenamide fumarate, tenofovir disoproxil fumarate and entecavir: which is the most effective drug for chronic hepatitis B? a systematic review and meta-analysis.","volume":"9","author":"Ma","year":"2021","journal-title":"J Clin Transl Hepatol"},{"issue":"5","key":"zoi220558r63","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy.","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"zoi220558r65","doi-asserted-by":"publisher","first-page":"c221","DOI":"10.1136\/bmj.c221","article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting.","volume":"340","author":"Riley","year":"2010","journal-title":"BMJ"},{"key":"zoi220558r66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.02.018","article-title":"UNOS down-staging criteria for liver transplantation of hepatocellular carcinoma: systematic review and meta-analysis of 25 studies.","author":"Tan","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"zoi220558r67","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","article-title":"Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.","volume":"23","author":"Tan","year":"2022","journal-title":"Lancet Oncol"},{"key":"zoi220558r43"},{"key":"zoi220558r64","author":"Marcellin"},{"key":"zoi220558r2","unstructured":"World Health Organization Global Hepatitis Report. 2017. Accessed May 20, 2020. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255016\/9789241565455-eng.pdf;jsessionid=6DB65DA61DB685B218A314037DBE0C09?sequence=1"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2793772\/tan_2022_oi_220558_1655908696.98483.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T22:20:35Z","timestamp":1700778035000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2793772"}},"subtitle":["A Reconstructed Individual Patient Data Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.19407","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]}}}